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ABSTRACT
Diepoxybutane (DEB), a known industrial carcinogen, reacts with DNA primarily
at the N7 position of deoxyguanosine residues and creates interstrand cross-links at the
sequence 5'-GNC. Since N7-N7 cross-links cause DNA to fragment upon heating,
quantative polymerase chain reaction (QPCR) is being used in this experiment to measure
the amount of DEB damage (lesion frequency) with three different targetsmitochondrial (unpackaged), open chromatin region, and closed chromatin region. Initial
measurements of DEB damage within these three targets were not consistent because the
template DNA was not the limiting reagent in the PCR. Follow-up PCR trials using a
limiting amount of DNA are still in progress although initial experimentation looks
.

...:i

promising. Sequencing of these three targets to confinn the primer targets has only been
successfully performed for the closed chromatin target and does not match the sequence
from NIH used to design that primer pair. Further sequencing trials need to be conducted
on all three targets to assure that a mitochondrial, open chromatin, and closed chromatin
region are actually being amplified in this experimental series.

9

INTRODUCTION
Th

1'0

'tL of lhi r' car h inyolY .. a t

Xln

rc enl y foun to e affecting wor '~r.'

bbcr and polymer indtrtri ~-. Dic-p xybutane. formed by th ;,

in the

of 1.3- Itacii n . is belie\ d to

Thi: proj ct atlem ts

quanritar\'e peR to map the damag ~ au,

u -e a tcchnique called

r~pli

et, iI.' of these experiment.,

,"II)

ation. and D\. -b'ndin2 mole ules i..· in rder.

;)nd Chromatin

De xyribonuclei a
C\

D~

0

1by thi - compound in mitochondrial am

nuclear chi 'ken 0:\ . 8efore elying into the p' in

D~A

metaboli m

us r lali\ I)' higher ratL of leukemia in th - \\. rkers

\' it action a. aD."

in-dLpth exploratiOJ ofD::<, .

\';\'0

'0 protein

prc-~nt

1

(D~A) i.=

U'

l.'m~r

ther in. D\A is a

\ 'hi 'h ar compo 'ed or a Ie x,/ri
nltrogcn

th ~ h r ditary ma erial of a ccll and e 1C d .
on tnIcted romnu

. e , ugar. a ph

baSeS. The purine bases, a

lcotld~

monome "

phat' group. an' n of four

nine and 2uanine. ar d ubi -ringed

tnJcnJre~

\\'hil'" the pyrimidin' bas ·:S, c:,tosinc and thymine. contain only a ingle ring (Figure I ).1 ~

1\'

\',1

11/

11'\.-/11
I)

~\

I H

I.'

r

II

f 1-1'--1 ,

t

o

o

II
I)

('-1' - ( 1 - . . JI

"-

Il

"'H

I

\,J-I

(t-J'-.l-{'f'

11-1'-1

(J

'1/

t

II

I'\.-'il
l

1 If

11\

(.tf

II

rohul

~:Ill)

Figure 1. ,u

1)"..\r1bO(lu .... ot .. I .....

I~OIlJ6

fc1und III D

\.

10

James Watson and Francis Crick first deduced the three-dimensional structure of
DNA in 1953 from the X-ray crystallography data of Rosalind Fran.kJin and the pre
existing rules for DNA developed by ElWin ChargafT. The DNA molecule is a double
stranded helix composed of two antiparallel phosphate backbones along its exterior and
pairs of nitrogenous bases (one from each strand) interacting in its interior. Each
phosphate backbone has a directionality with the end containing a tenninal phosphate
group called the 5' end and the end containing a terminal deoxyribose sugar the 3 'end.
This double helix also has two different sized channels that spiral around the molecule
called the major and minor grooves. In the interior, cytosine fOnTIS three hydrogen bonds
with guanine and adenine foms two hydrogen bonds with thymine which serve to
stabilize. thejouble helix by counteracting the repulsive forces caused by the prevalent
negative charges along its phosphate backbones. I
Most of the DNA within an eukaryotic cell is contained within the cell's nucleus
and is called genomic or nuclear DNA. Some semi-autonomous organelles, though,
contain their own genetic material similar to prokaryotic DNA in structure. I All
eukaryotes except one species of Amoeba contain mitochondria, organelles thought to
have once been endosymbiotic bacteria. Mitochondria catalyze the fonnation of
adenosine triphosphate (ATP) through oxidative phosphorylation and contain their own
DNA to form the necessary protein components for such a process. Like prokaryotes,
mitochondrial DNA is contained in one closed circle about 5 !Jrn in length in higher
organisms and holds about 70 genes or sections of DNA that encode only one product,
usually a protein (Figure 2). Genes present in the mitochondria are not found in the
nuclear genome, but the mitochondria still relies on proteins like DNA polymerase
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It is believed that the histone proteins are chemically modified to adjust the level
of DNA condensation and thus control transcription and translation. These proteins are
known to undergo methylation, phosphorylation, polyADP-ribosylation, ubiquitylation
4

(covalent attachment of the nuclear protein ubiquitin to H2A), and acetylation. H3 and
H4 are the only histone proteins known to be methylated in vivo. Methylation occurs at
several specific lysine residues and the net effect of this methylation is a change in the
hydrophobicity of these lysine side chains while conserving the net positive charge.) HI
is the most phosphorylated of the histone proteins and several different sites of
phosphorylation (serine, threonine, histidine, and possibly lysine or arginine) have been
observed. Serine and threonine phosphorylation of H I appear to be the most important
types

ofph~horylation since

they help start the process of cell division by triggering

chromosome condensation. 3•6 Very little is known about the effects ofpolyADP
ribosylation and ubiquitylation but it is suggested that ubiquitylation ofH2A might
prevent solenoid condensation. 6
Tbe last form of histone modification, acetylation, has a more documented
connection to active and inactive chromatin. Reversible acetylation has been observed in
all four types of histone proteins that form the octamer in nucleosomes. Specific lysine
residues are converted into acetyl Iysines thus reducing the overall positive charge of the
histone. This reaction would suggest that acetylation of histone proteins causes DNA to
dissociate from the octamer core in nucleosomes and thus would be involved in DNA
synthesis and transcription.) Hebbes et al. (1988) found a direct correlation between
transcriptionally active genes and acetylated core histones in embryonic chicken
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DNA is stored in a series oflinear chromosomes. As a result, DNA replication instead
starts at many different origins simultaneously. I
A replication fork is created and expanded outward by enzymes called helicase
and gyrase (Figure 8). Helicase breaks the hydrogen bonds between the complementary
strands of DNA (via the hydrolysis of ATP) and splits apart the double-stranded DNA
molecule as a result. Gyrase alleviates the coiling strain caused by helicase unwinding
the DNA by breaking a phosphodiester bond on one strand, passing the other strand
which is still intact through this opening, and then reforming the cleaved bond. The
DNA molecule cannot immediately reform a double helix because of the presence of
single-stranded DNA binding proteins which bind preferentially to single-stranded DNA
and cover fQJg exposed nucleotides each. 1O
Once the strands are separated, a type of RNA polymerase called primase places
short RNA oligonucleotide sequences called primers on each DNA strand. l With a
primer in place, DNA polymerase III catalyzes DNA synthesis in a 5' to 3' direction. For
the parent strand called the leading strand., net DNA synthesis proceeds in a 5' to 3'
direction as the replication fork moves along the original DNA molecule. As a result,
DNA can be synthesized continuously along this template strand. For the other strand
called the lagging strand, though, the net synthesis of DNA must proceed from 3' to 5'.
To accomplish this, a series of smaller DNA fragments are made in the usual 5' to 3'
direction (each started from its own RNA primer) called Okazaki fragments. Once both
DNA strands are synthesized, DNA polymerase I replaces all RNA primers with the
appropriate DNA nucleotides in a 5' to 3' direction. DNA ligase then seals all nicks or
(missing phosphodiester bonds) left behind by DNA polymerase I.l.l O
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mutations in these genes Willed oncogenes cause the hyperactivity or overexpression of
these enhancing proteins and thus promote unhindered cellular proliferation. s One
common example of an oncogene in many cancer cells is a mutation in ras, a G-protein
involved in the activation of MAP kinase. The oncogene eliminates the G-protein's
GTPase ability so that the G-protein is always active. As a result, MAP kinase also
remains activated and cellular gro\\>th and proliferation can now proceed unchecked.
Thjs oncogene is present in nearly half of all lung and colon tumors and almost all
pancreatic cancers. 2
Tumor-suppressor genes code for proteins that act as cell cycle brakes to prevent
overproliferation. 5 Mutations that produce inactlve forms of these proteins and thus
allow unre~cted mitosis and cytokinesis are often recessive so a mutation must occur in
both copies of the gene for these elements to be shut off. One well-known example of a
tumor-suppressor gene is p53.1.2 p53 acts as a transcriptional activator that regulates
cellular division as a G\ checkpoint that stops DNA replication if there is DNA damage
and as an initiator of apoptosis (programmed cell death) if the DNA damage is too
4

extensive.1. Mutations to this gene cause the cell cycle to continue unabated. despite the
accumulation of genetic damage. Thus, inactivation ofp53 promotes Wlncer since the
series of mutations necessary to initiate tumor growth can accumulate over many cellular
generations.l.2.4 p53 mutations are estimated to occur in at least half of all cancer cases. I
The shutting down of apoptosis is a common feature in many cancer cells.
Apoptosis limits the life span of cells thus preventing the accumulation of a large number
of mutations in a single generation. Furthermore, apoptosis would nonnally cause the
destruction of any cancerous cells present in an organism because of the large amount of
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Finally, there are some RNA and DNA viruses called oncogenic viruses that alter the
DNA of the host cell and shut down the nonnal cellular controls over proliferation and
differentiation as a result. 12 Examples of oncogenic viruses include smallpox,
papovaviruses, adenoviruses and herpesviruses. 4•12
There are currently three major types of treatment options available to cancer
patients. Surgery is used when the cancer has not yet metastasized and the location of the
cancer is still well defined... I 1,12 A method dating back to the Greeks, surgery is used to
remove all cancerous cells from the body and thus cure the patient by completely
eliminating all malignant tissue. Surgery can easily fail as a treatment, though, if some
cancer cells are left behind. 12 Radiation therapy is also employed in cancer treatment
since

~dia~n

is deadJiest to cells that have a high division rate. Thus, cancer cells

should have a higher susceptibility to radiation than most other cells within the body.lt,12
Also since radiation treatment can be localized to one area of the body, many of the
tissues in a patient can be spared from massive damage, I I Bone marrow and intestinal
cells, though, naturally proliferate faster than even some cancer cells and thus are
extremely vulnerable to radiation treatment. Radiation damage to these tissues cause
some of the severe symptoms that many cancer patients experience during their
treatment. 12 Finally, chemotherapy uses toxic chemicals to 1011 rapidly dividing cells
within the body. These drugs target specific points within the cell cycle and arrest cell
division. Ideally, this should cause the cancer cells to die before the normal body cells.
Some cancer cells, however, have high resistance to these drugs, and the side effects from
treatment are similar to those from radiation therapy but much more systemic. In most
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increases proportionally with transcriptional activity in chromatin. 14- 16 In fact, DNA
complexed wlth proteins has a lower binding affmity for ethidium bromide than naked
DNA. I ?
The overall lower binding affinity of ethidium bromide to chromatin is attributed
to the presence of his tones. In fact, lysine-rich histones (H 1, I-UA, and H2B) inhibi t
ethidium bromide binding the most. 17 Positively charged histones interact with and thus
essentially tie up the negatively charged DNA phosphate backbone. Consequently,
ethidium bromide intercalation is weakened by the absence of electrostatic attraction with
the DNA's phosphate groupS.16 It is estimated that 20% of the DNA in chromatin is
inaccessible to ethidium bromide because of this histone effect, but the linker region
betwe~

nweosomes where most histone proteins do not bind actually has a higher

binding affinity for ethidium bromide than naked DNA. 18• J9
The binding of etbidiwn bromide causes significant changes to the structure of
both DNA and chromatin. Upon ethidium bromide binding to DNA, all internal motions
are hindered over a 2 base pair range around the binding spot, possibly causing a
relaxation in chromatin packaging. 19,20 Furthennore, ethidium bromide unwinds the
DNA double helix by 26°, causing a slight bending toward the major groove. 2l As a
result, the accessibility of DNA within nucleosomes to enzymes like nucleases and
DNases is adversely affected. 22 Ethidium bromide follows a cooperative mode of
binding - as the DNA within the linker region relaxes from ethidium bromide
intercalation, the nucleosomal DNA becomes less tightly bound to the histone core and
allows more ethidium bromide to bind. 19 The combination of DNA stiffening arId

2S

unwinding within the nuc1eosome prevents the DNA from bending around the histone
octamer properly.21
Eventually, a critical number of ethidium bromide molecules bind to the
nucleosome (about 9-14) and cause the histone core to transfonn from an oetamer to a
hexamer as one copy of H2A and H2B are released. 13 •2U3 It is theorized that ethidiurn
bromide binds in equal amounts to the linker segment on either side of a nucleosome and
this symmetrical binding loosens the association between DNA and the histone octamer.
A critical level of ethidium bromide intercalation then occurs randomly at one end. A

H2A1H2B dimer is released as a result, and the histone core shrinks to a hexamer. This
transformation allows for more ethidium bromide to bind to the nucleosomal DNA,
causing it Utunwind and stiffen even more. Eventually, the DNA can no longer wrap
around the histone core and the nucleosome falls apart Ethidium bromide can
completely disrupt DNA packaging and cause DNA mutations in vivo making this small
molecule a significant danger to biological systems. I)

AJkylating Agents
Alkylating agents include syn-BPDE and trans-BPDE, two metabolites of
benzo[a]pyrene, a polycyclic aromatic hydrocarbon found commonly amongst
combustion products like cigarette and chimney smoke. While this molecule does not
cause appreciable DNA damage by Itself, benzo[a]pyrene is activated during in vivo
metabolization by cytochrome P450 (Scheme 1). The process begins with the formation
of a trans-7,8-diol which is further acted on by cytochrome P450 to yield a mixture of the

syn- and anti-diol-epoxides,

(±)-7~,8a-dihydroxy-9a,1Oa-epoxy-7,8,9,10

26

tetrahydrobenzo[a]pyrene (syn-BPDE) and

(±)-7f)8a-dihydroxy-9~,1O~-epoxy-7 ,8,9,10

tetrahydrobenzo[a]pyrene (anti-BPDE), respectively.24.27 It is believed that the antistereoisomer is formed in greater amounts, indicating that cytochrome P450 is
stereospecific. 27 Earlier reports claimed that the syn- isomer was the cancer-causing
metabolite, but more recent papers implicate both BPDE isomers instead with the antiform being considerably more carcinogenic. 26-28

cytochrome
P450

HO'"
OH
Q.e nzo(ajpyrene

......

be nzo[ajpyrene-7,8-diol

cytochrome P450

HO'"

HO'"

OH

OH
syn-BPDE

anti-BPDE

Scbeme 1. Metabolic activation ofbenzo[aJpyrerte in Vi~'O?4

As a result, research has concentrated mainly on anti-BPDE. This metabolite
primarily interacts with a cell's DNA and prefers to bind covalently through its epoxide
ring to the N2 position of guanine in DNA within the minor groove (Figure 12).28.29
Cytosine and adenine arc also DNA targets but only make up about 5-10% of all anti

27

BPDE DNA binding sites in vivo. 3o Anti-BPDE prefers a pyrimidine directly upstream
(5' end) oftbe targeted guanine and another guanine directly downstream (3' end).3o.31

Poly G sequences of four or more base pairs seem to be preferred as well. 30 Binding of
ann-BPDE to DNA causes small localized distortions as the DNA double helix denatures

slightly.29
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Figure 12. Diagram of deoxyguanosine bound to ullli-BPDE. The N2 of guanine will atlack syn-BPDE instead from
above tbe ~Ianar BPDE molecule. The R subgroup represeots the deoxyribose sugar and the phosphate group of the
nucleotide. :!lI

Anli-BPDE binds at a much lower rate than syn-BPDE to chromatin (as much as

two times lower in some studies) indicating that the confonnation of DNA therein affects
carcinogen accessibility .32.34 Only 25% of the anti-BPDE binding to chromatin reacts
with proteins, indicating that DNA remains its primary target,33.35 Protein binding is
lowest on HI, the most lysine-rich of all the histone proteins. 35 This diol-epoxide also
prefers to bind in vitro to the linker region between nucleosomes presumably because the
histone octaIner partially blocks access to the minor groove. 34 -37 In vivo studies, however,
indicate that this binding preference for linker DNA is lost as the number of adducts
changes over lime.

37

-Ml

This loss of preference is caused by DNA repair since anti-BOPE

lesion extraction also seems to occur preferentially at the linker regions. 39-41 Not
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surprisingly, this diol-epoxide also prefers binding initially to open areas of chromatin
although significant binding (35%) does still occur in more condensed regions?9..38

Cross-linking Agents
The remainder of this introduction will focus on a class of molecules that bind to
DNA in a very distinctive way. As already seen above, some molecules like anti-BPDE
can covalently bind to nucleotides on one DNA strand to create monoadducts. For the
rest of the molecules herein, this type of binding occurs as an initial step. The process
can then be repeated with the same or opposite strand to create a wvalent linkage called a
cross-link. Many of the wmmon chemotherapy drugs used today in cancer treatment
follow,thi~ique

binding pattern.

Nitrogen mustard:
Nitrogen mustard (HN2) was originally developed as a derivative of mustard gas
during World War I in an attempt to create a deadlier weapon. Post-mortem examination
of nitrogen mustard gas victims revealed that bone marrow and other areas containing
quickly dividing cells were the toxin's primary targets. 42 .43 Burn patterns by nitrogen
mustard on human epidennis also resembled those commonly formed by radiation. As a
result, testing against leukemia and other cancer forms began soon after. Over time,

I

CI~N~CI
Mechlorethamine

CI

Uracil mustard

Quinacrine mustard

Figure 13. Structures of selected nitrogen muslards.
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nitrogen mustards became a class of standard chemotherapy drugs as more and more
variations were produced from the starting model, mechlorethamine, which is now
considered the simplest of the nitrogen mustards (Figure 13).'12 Toxicity testing of HN2
revealed that its side-effects were only slightly worse than those from radiation therapy.44
Moreover, Hodgkln's disease patients who are treated with HN2 have a 8-40 times
greater risk of developing leukemia depending on the number of chemotherapy cycles
with HN2 they undergo.

45

HN2 reacts with the N7 position of guanine found in the major groove of DNA
and thus forms a monoadduct similar to anti-BPDE.

46

-48

This covalent linkage proceeds

via a 3-membered cyclic aziridiniurn intermediate (the rate-determining step in the entire
process) ~ich is nucleophilically attacked by the N7 in guanine to open the strained ring
(Figure

14).43,48.49

I
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CI
Figure 14. Cyclization of nilrOgen mustard mechlorethamine info azindiniwn

carion: J ·48

HN2, however, can undergo another reaction (Scheme 2). Another cyclic
aziridinium ring can form and react with another guanine at the N7 position on the
opposing strand to create a covalent interstTand cross_link. 43 •48,50 This result was
confirmed when DNA exposed to HN2 and denatured reformed the duplex
spontaneously, indicating that there was a covalent linkage across the two strands guiding
them back together.

51

Studies have revealed that the ratio of interstrand cross-links to

monoadducts in tumor cell lines is only about lS%? This low cross-link formation rate
can be explained by the S'-GNC preference (where N is any nucleotide) ofHN2 in

30

forming cross-links within both restriction fragments and nucleosomes. HN2 can
covalently bind to any deoxyguanosine but only fonns cross-links at a few of those
sites. 53 •56 The cross-linking distance for S'-GNC exceeds the length of HN2 (which is
why the cross-linking preference was long believed to be S'-GC or S'-CG) so localized
distortions of the double helix (a 12.4° to 16.8 0 bend) must occur. 56S7
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While the sequence preference ofHN2 does not change due to packaging effects,
the actual amount of cross-linking in vitro and in vivo is affected. Cross-links [ann most
efficiently in regions that are highly transcribed. 52 Additionally, binding intensity is two
to three times lower in nucleosomes than naked DNA, indicating that the histone octaIner
impedes HN2 binding, possibly from the compression of the DNA's major groove at
places. 55
The cytotoxic effects ofHN2 have been measured within several biological
systems and clearly show the drug's potency. HN2 has been shown to interfere with the
interaction between RNA polymerase and the lac UV5 promoter causing transcriptional
blockage. 58 Furthennore, HN2 interstrand cross-linking in RJ"\lA, single-stranded DNA,
or doubl~tranded DNA bacteriophages can cause total viral inactivation. 59 Especially
relevant to cancer treatment, resistance to HN2 has been measured in cultured tumor cells
with a half-life of two to three months. This resistance, however, does not hinder the
effects of other chemotherapy drugs and its mechanism is still uncertain. 6o

Cisplatin and trans-DDP:
Platinum compounds were first investigated as possible chemotherapy drugs
when Rosenberg el al. noticed that platinum electrodes hindered the cell division process

.

in E. coli. It was deduced that the electrolysis products from the platinum electrode
inhibited DNA replication somehow since the bacteria continued to grow into long

filaments. 61 As a result, cis-dichlorodiammineplatioum (cis-DDP or cisplatin) and trans
dichlorodiammineplatinum (trans-DDP) were tested for cancer treatment (Figure 15).
While trans- DDP had no significant anti-tumor effects, cisplatin was found to be as
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Figure IS. Sttuctures of cis-DDP and /Tons-DDP,62

effective as any other chemotherapy drug for ovarian, bladder, lung, and cervical cancers,
Toxicity swdies showed that short-term symptoms from cisplatin treatment include
nausea and vomiting while sterility and peripheral nerve damage were possible long-term
SI'de

a'
62
ellects.

Comparative studies of cisplatin and trans-DDP binding to chromatin have
...;i'

revealed slightly different binding patterns that could explain their differing activity in
vivo. In one study, both isomers reacted initially with H3 at low concentrations near or at
cysteine residues but trans-DO? formed H3 dimers with.in the histone core while
cisplatin did not. Furthermore, eth.idium bromide binding decreases for DNA exposed to
either cisplatin or trans-DDP, indicating that both isomers also target the DNA
molecule. 63 Another study found that cisplatin binds primarily to DNA with a saturation
point of 45 platinum atoms per nucleosome core. Additionally, cisplatin only forms
H31H2A cross-links at high concentrations. Trans-DDP, on the other hand, catalyzes
mostly DNA-histone and histone-histone cross-links. This isomer primarily formed
H31H2A cross-links although some H2BIH4 cross-links were also observed..64 Both
compounds can prevent nucleosome formation when exposed to the separated histones
and DNA but do not destroy already existing nucleosomes upon exposure. 65
Interestingly, cisplatin binds to certain areas of chromatin more than naked DNA
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although trans-DDP does not show this binding pattern.

65

Cisplatin also tends to

causegreater structural changes in packaged DNA than trans-DDP and binds
preferentially to the linker region in chromatin at the same rate as with naked DNA.

66 67
.

Cisplatin's stronger preference for DNA could explain its anti-tumor activity since DNA
interaction has been often implicated in cytotoxic effects.
Both isomers do form some interstrand cross-links in DNA but only in 10-20% of
all platinum bound.

68

Trans-DDP cross-links DNA between a deoxyguanosine at N7 and

its complementary deoxycytosine while cisplatin cross-links two deoxyguanosine bases
at the N7 position with a sequence preference of 5'_GC.54.68.69 Both isomers bind to the
N7 position of the guanine first and then react with cytosine or guanine on the opposite
strand to~mplete the interstrand cross-link (Scheme 3).68 While trans-DDP fonns
interstrand cross-l inks only half as fast as cisplatin, it fonns twice as many of these cross
links overall indicating that the trans-isomer is the more effective interstrand cross
linking agent. 68.69
Both cisplatin and trans-DDP inhibit DNA synthesis in vitro at (dG)n (n::: 2) and
d(GpNpG) sequences respectively. As the ratio of platinum-to-phosphate group
increases so does the level of inactivation, and monofunctional forms of the drug (forms
that can only create one linkage to DNA) do not inhibit DNA synthesis at all indicating
that some sort of cross-linkage is still occurring.

70 7l
.

However, this DNA synthesis

inhibition cannot be explained exclusively by interstrand cross-links. More recent studies
have discovered that cisplatin forms intrastrand cross-links between adjacent
deoxyguanosines at the N7 positions (65%) with minor lesions at AG (25%) and GNG
(6%) and these lesions have serious inhibitory effects on DNA cleavage by exonuclease
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ITI, Pst I, and BamHl. 72 -78 dG/dG intrastrand linkages cause a 40 0 bend and base pair
(6%) and these lesions have serious inhibitory effects on DNA cleavage by exonuclease
14

unstacking within the DNA double helix. 13 •

Cisplatin binding also causes the degree of

DNA supercoiling to change in circular DNA and the DNA molecule shortens by as
much as 50% as a result.

79

trans-DDP also can fonn dG/dG intrastrand adducts although
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primarily at 5'- GNG sequences. Cisplatin, however, inhibits DNA synthesis twice as
well as trans-DDP indicating that the trans-isomer either forms fewer intrastrand cross
links overall than cisplatin or its intrastrand cross-links (which tend to span three
1

nucleotides instead of two) do not inhibit the synthesis process as effective!y.70.7 The
first scenario seems to be more likely since RNA polymerase II has been found to be
inhibited at both initiation and elongation by 5'-GNG lesions fonned by cisplatin. 80
Either scenario, though, would make trans-DDP a much less potent anti-tumor drug. 70.

71

Since cisplatin is now commonly used in chemotherapy, several studies in the
past twenty years have looked at the cellular response to cisplatin over time. Within 24
hours, 56-85% of the lesions fonned by cisplatin are repaired in

ViVO.

81

Resistance to

cisplatin Ul'several tumor lines has been accomplished in vitro and this resistance
mechanism is slightly better understood than the one for nitrogen mustard. Resistant cell
lines have increased expression ofXPE binding factor which binds to damaged DNA and
initiates the cellular repair process. This increased expression of XPE is one of the first
modifications gained in the resistance process but does not continue to increase as
resistance builds indicating that XPE binding factor is only one of many elements
involved in this selective process. 60 ·&2

Mitomycin C:
In 1956, Sugawara and Hata described the characteristics of Streptomyces

caespitosus which produced a new antibiotic called mitomycin that had some anti-tumor
properties. 83 Mitomycin A and B had already been isolated, but a third fraction (fraction
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X) was not characterized until 1958. Distinguishable by its blue-purple color, this
fraction was very stable at a wide range of temperatures and worked best at pH of 6 to 7.
Dosages of 40-1 000 I-tgfkg/day in cancer patients greatly extended. their survival time but
this new compound also showed a delayed tDxicity that caused death two to fourteen days
after a lethal dose was administered. 84 Renamed. mitomycin C, its structure was
determined conclusively four years later and was found to be very similar to mitomycin

A and B (Figure 16).85

o
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N-H
Mitomycin A

Mitomycin B

Mitomycin C

Figu re 16. Structures of three mitomycin compounds from StreplOmyces caespirosus. K5

Mitomycin C, when administered. to healthy mammalian cells, causes the
fonnation of giant cells. These cells show nuclear fragmentation and, more importantly,
some DNA depolymerization, suggesting that mitomycin C inhibits DNA replication but
not cellular growth. 86 Compared to actinomycin D (another chemotherapy drug),
mitomycin C inhibits mitosis and DNA replication in vitro much faster although its
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depolymerization effect on DNA was discounted as the cause. 87 Further comparative
studies found that mitomycin C is as or more effective than actinomycin D, sarkomycin,
and carzinophilin against tumors at therapeutic levels. Marked levels of inhibition were
observed in 21 of the 35 types of tumors tested. with complete inhibition in Walker
carcinosarcoma, Jensen sarcoma, Iglesias functional ovarian tumor, and Friend virus
leukemia (to name a few).88

In vivo studies of mitomycin C found that the drug concentrates more in tumor
cells than normal ones and that liver microsomes can inactivate this compound although
inactivation is also seen in the spleen, kidney, brain, and heart 89 Common side effects in
animals include hematopoiesis, anorexia, weight loss, diarrhea, intestinal damage, and
dehydratUln.

90

Despite its effects as an anti-cancer drug, mitomycin C can actually

induce cancer within healthy skin cells although not as well as some other chemotherapy
drugS.91

Before interacting with DNA) mitomycin C is first chemically reduced (Scheme
4). In this process, the quinone ring is reduced first and then the methoxy group

spontaneously lost to form an indole system and re-establish the molecule's aromaticity.
Addition of a proton at this point serves to prime the aziridine ring for nucleophilic
attack.

92

This process is achieved commonly in vitro by using Na2S204 before exposing

mitomycin C to DNA. 93
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As with mechlorethamine and cisplatin, mitomycin C fonns DNA cross-links

(Scheme 5). Experiments have shown that DNA with a mitomycin C cross-link
spontaneously reforms after denaturation, indicating that mitomycin C is an interstrand
cross-linker.

94

Mitomycin C covalently attaches to the N2 position of deoxyguanosine
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initially to fonn a monoadduct (like anti-BPDE) and then reacts with another
deoxyguanosine also at the N2 position on the complementary strand to complete the
cross-linkage. This means that mitomycin C is positioned in the minor groove. 95.96
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Mitomycin C has been found to bind to 5' -CG sequences and prefers this
sequence over 5'-GC. 54.95,%,98·102 Original molecular modeling attempts found no energy
difference between cross-hnks at these two sequences, but the confonnational differences
between 5'-CG and 5'-GC seem to favor cross-linking at the fonner since the distance
between the N2 amino groups in the deoxyguanosines is shorter.99•1OO Further testing
found that the sequence 5'-(purine)CG(pyrimidine) is favored with deoxythymidine
preferred over deoxycyridine on the 3'end. \01 This explains the greater frequency of
cross-linking seen in 5'-GCGC over 5'-TCGA.(OO The only exception to this pattern is
the sequence 5'-(CG)n since the number of possible binding sites is increased. tOI
Cytosine methylation also increases cross-linking frequency by 1.5 to 2 times at the
consensus-,eequence 5' _CG. 102 Interestingly, mitomycin C cross-linkages still allow the
bases to stack properly within the DNA double heli~ but cross-linking is inhibited by a
factor of5 to 10 in nuc1eosomes as compared to naked DNA. 55 .%

Diepoxybuta ne:

I,3-butadiene, a colorless gas that has a faint gasoline smell, is a common by
product of petroleum processing. While low level exposure can cause eye, ear, and throat
irri tation, high levels of 1,3-butadiene inhalation can lead to nerve damage, nausea,
fatigue, headache, decreased blood pressure and pulse, and even unconsciousness. 1,3
butadiene is also a known carcinogen and can lead to serious birth defects. t03 The U.S.
produced 1.2 billion kilograms of this compound in 1987 and it is commonly used to
make rubber and nylon. 104 In the process, 1.7 million kilograms of this gas is
accidentally released annually, mostly due to equipment leaks. 105
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As a result, the effects of 1,3-butadiene on industrial workers have been the focus

of several health studies. In 1993, the National Insh tute of Occupational Safety and
Health of the Centers for Disease Control and Prevention measured the level of 1,3
butadiene in several monomer, polymer, and end-user factories. Levels ranged from
0.005 to 374 ppm (all below OSHA's maximal pennissible level) and over 88% of testing
sites had levels below 2 ppm. 106 The average American is also exposed to 44 nanograms
of 1,3-butadiene daily (1/1 0 of the hazardous level established by the state of California)
since l,3-butadiene derived polymers are commonly used to package, transport, and
protect food. \07
Studies of exposed industrial workers reveal that l,3-butadiene does have serious
health

e~ts.

The gas is known to cause DNA repair defects in these workers (although

smoking exacerbates this problem even more) and there is a correlation between the
amount of I ,3-butadiene exposure and the risk for leukemia. lOS-I 10 Animal studies have
only further supported the carcinogenic effects of 1,3-butadiene. It is known to induce
cancer in mice (6.25 to 1250 ppm) and cause the same effects in rats at higher levels
(1000-8000 ppm) possibly because of differences in how 1,3-butadiene is metabolized in
vivO.

III 1l2
.

Furthermore, constant exposure to 1,3-butadiene increases the likelihood of

tumor formation in the heart, lymph nodes, lungs, stomach, and ovaries ofmice. l13
While it has been noted that I ,3-butadiene is a relatively weak genotoxin in vitro, it is
believed to be much more potent in vivo and causes point mutations at Aff base pairs,
AT to GC transitions, and AT to TA transversions. 114 ,IIS

42

The toxicity of 1,3-butadieoe is believed to come from some of its metabolites in
vivo. 1,3-butadiene is converted in the liver by several different cytochrome P450
enzymes to butadiene monoxide (EB) which then can be further converted into
diepoxybutane (DEB), a process that relies heavily on the presence of both NADPH and
O2 (Scheme 6).116-119 From there, DEB can be converted to 3,4-epoxy-l ,2-butane-diol
(EBD) in the endoplasmic reticulum by an epoxide hydrolase.118-12o The stereochemistry
of this process has been studied in mice and rats where DEB is fanned in higher amounts
in mice than rats. In mice, the meso- isomer of DEB was found to be produced in much
greater amounts than both the (R:R)- and (S:S)- isomers while no such pattern was found
in rats. It is believed that stereochemical differences like these in [,3-butadiene
metaboli~

within mice and rats might help account for the observed mutagenic

differences between these species in vivo. 121
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Scheme 6. Partial ooetabolic pathway of 1,3-buLadiene in vivo as it is convened sequentially into EB, DEB, and
EBD. II 8-121l

43

The three metabolites EB, DEB, and EBD have received much attention as the
causes of I)-butadiene damage in vivo since they all have been found to be mutagenic. 122
Since the focus of this srndy is DEB, EB and EBD will be considered briefly first. EB is
considered much less stable than DEB and is known to cause AT to TA transversions,
point mutations, and small deletions in rat and human cells in vitro. l15 ,123,124 The N7 of
deoxyguanosine attacks the epoxide ring of EB in an SN2 reaction (at the outer carbon
more often than the inner one) to create a monoadduct 125,126 The second-order rate
constant for this reaction is ten times higher than the analogous one for DER 123 The
monoadduct created by EB has been shown to stop the action of three different E. coli
polymerases in vitro which shows its potential as a carcinogenic toxin. The same effect
was also ~n with EBD.

127

A study of mouse IWlg exposed to EB, DEB, and EBD

suggests that 98% of the N7 deoxyguanosine adducts are fonned by EBD indicating that
EBD could be tbe most reactive of these three metabolites. 128 However, EBD requires

100 times the concentration of DEB for the same amount of mutagenic activity in CHO
K1 cells. Mutations caused by BDE include exon deletion, GC to AT transitions, and AT
to GC transitions. 129
DEB is a toxic, colorless liquid that is known to be carcinogenic and

mutagenic. DO It is mutagenic at levels 100 times lower than that of both EB and EBO
and causes point mutations, small and large scale deletions, GC to AT transitions, and AT
to TA transversions in vitrO. 115 ,l22.124,129 In fact, DEB is the only metabolite of 1,3

butadiene found to date that causes all of the types of mutations seen in mice exposed to
I,3-butadiene.

122

Furthermore, 43-58% of human and Drosophila cells exposed to DEB

in vitro acquire deletions in their genome that can range anywhere from 50 to 8000 base
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pairs while constant exposure of rats to DEB for 12 weeks caused the death of all test
subjects within 18 months presumably from the massive tumors found during post
mortem examinations. 122.131,132 Additionally, 4-18% of tomato seeds exposed to DEB
produced adult plants with mutations and caused delayed germination and fruit
production along with some chlorophyll deficiency in all adult plants. 133
DEB is the only 1,3-butadiene metabolite that contains two epoxide rings, giving
this compound the ability to react at two different locations. DEB reacts initially to fonn
a monoadduct at the N2 or N7 position in guanine and N3, N6, N7, or N9 in
adenine.129.134.139 As the amount of DEB increases, so do the number of adenine adducts
formed although the same is presumably ttue for the guanine adducts as welL 137
.

L~ley

and Brookes in 1967 found that DNA exposed to DEB renatures

spontaneously after denaturation because of a covalent linkage between deoxyguanosines
on complementary strands at the N7 positions and confinned later by Park and
Tretyakova in 2004 (Scheme 7).140.1 41 DEB cross-links DNA preferentially at 5'-GNC
sequences (where N is any nucleotide) just like HN2 although DEB is less efficient 142.143
Despite this apparently lower cross-linking rate, 17 coliphages exposed to 20 mM DEB
for 2 hours actually had interstrand cross-links in 35% and caused death in 96% of the
phages used.

143

DEB is actually believed to be more mutagenic than EB (despite the

lower rate constant) because of DEB's ability to form these cross-Jinks and differences in
the repair ofEB and DEB adducts. l38 Interestingly, nucleosome structure does not seem
to hinder DEB alkylation and cross-linking of DNA to any large degree (within a core
particle only).I44
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dG to dG cross-link
Scbeme 7. Interstrand cross-linking reaction of DEB between two deoxyguanosines at the N7 position. The
R subgroup represents the deoxyribose sugar and phosphate group of the nucl cotide .140

DEB can also make intrastrand cross-links in vitrO. J39 ,14S DEB intrastrand cross-

Jinks between the N2 positions of deoxyguanosines can block the activity of three
different E. coli polymerases in vitro (Figure 17).139 Furthermore, DEB intrastrand crosslinks between the N6 positions on deoxyadenosines cause A to G mutations at the 3'
adducted base at a frequency of 50-90% (Figure 17).145 The mutagenic properties of
DEB, as a result, are primarily from its ability to [onn both intrastrand and interstrand
cross-links at a variety of positions.
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Figure 17. Two intrastrand lesions caused by DEB. DEB can cross-link two deoxyguanosioes at the N2
position (left) and two deoxyadenosines at the N6 position.139.1~5

Interestingly, it has only been in the last five years that DEB has been implicated
in current chemotherapy methods. It is now believed that treosulfan, a common ovarian
cancer drug, is metabolized under physiological conditions to DEB (Scheme 8). In this
form, treosulfan targets the DNA within tumor cells, creates an interstrand cross-link, and
causes cell death. 146
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Scbeme 7. Activation oftreosulfan in vivo (or in vi/TO using NaOH at 1.33:1 ratio).I....

Experimental Goals
The goal of this research project is to use quantitative PCR (QPCR) to determine
the damage caused by DEB in the cytochrome b domain of mitochondrial DNA and the

f3-g1obin domain of nuclear DNA Since N7 alkylated DNA is unstable at 90°C (the
melting phase during thermal cycling) and DEB bound to DNA can hinder the action of
DNA polymerase, QPCR will only amplify DNA molecules that do not contain a DEB

lesion. By labeling one primer with a radioactive phosphate group, the relative amount of
DNA produced by PCR (compared to a control) can be quantitated to calculate the
amount of damage incurred by DEB exposure. This study focuses on unpackaged

47

mitochondrial DNA and regions of both open and closed chromatin to detennine the
effects of DNA packaging, DEB concentration, and exposure time on the cross-linkjng
action of DEB. Moreover because of the fragmentation that occurs when DNA samples
with N7-N7 cross-links are heated, QPCR might also be able to act as a stop assay and
thus used to map out the positions of the cross-linking lesions by running out the QPCR
fragments on a large polyacrylamide gel. This study will investigate this possibiJity as
well. Finally, this study represents the first intensive attempt of our lab to develop QPCR
into a tool for measuring the action of DNA cross-linkers. If this method proves
successful and feasible, its potential uses in the study of cross-linking agents could be
immense and powerful.
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MATERIALS AND METHODS

Chicken liver homogenate preparation
Approximately 1 gram of shavings from commercially-obtained frozen chicken
I iver was added to 2.5 mL of iced., filtered, and autoc1aved 1x PBS (137 mM NaCI, 2.7

mM KCI, 11.9 roM phosphate, pH 7.4). This mixture was then homogenized using a 21

gauge needle until the solution was smooth. After the total volume was brought up to 10

mL using more Ix PBS, the solution was spun for 10 minutes at 1000g and 4°C. The
supernatant was stored at -20°C in 1.5 mL microcentrifuge tubes until needed.

...:i..

DEB incubation (vary [DEB] or incubation time)
Fresh DEB solutions were prepared each time from a 95% stock solution. The
DEB stock solution was used for a fmal250 mM cellular DEB concentration, a 1110 DEB
solution (dilution performed with dH20) for a 25 mM concentration, a l/ I 00 DEB
solution for a final 2.5 mM concentration, and a 1/1000 DEB solution for a final 0.25

mM concentration. Ninety-eight J.l.L of chicken liver homogenate was combined with 2
jJ.L of DEB stock or a freshly diluted DEB solution (or dH 2 0 if it was a control sample),
vortexed briefly, and incubated at 37°C for 30 or 60 minutes if varying [DEB]. If
varying incubation time instead, full DEB stock was used for all experimental samples.
If all of the samples were not undergoing any DEB exposure, this incubation step was
skipped completely.
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10% Chele.r: extraction protocol
DNA extraction began with micfocentrifuging 100 ilL of liver homogenate or 98
ilL of liver homogenate and 2 ilL DEB or dH20 for 2 minutes. The supernatant was
removed and discarded while the 100

ill of 10% Chelex solution was added to the pellet.

The mixture was vortexed briefly, incubated at 3rC for 10 minutes, vortexed briefly
again, and placed in a boiling water bath for 8 minutes. After cooling at room
temperature for 2 minutes, the mixture was vortexed and then placed in a microcentrifuge
for 30 seconds. The supernatant was then ethanol precipitated. A 1110 volume
(compared to the sample being precipitated) of 3M NaOAc (pH 5.2) and 2 volumes of
100% EtOH were added to the DNA solution and vortexed briefly. The solution then sat
in a ~20~ freezer for 30 minutes and spun at 4°C and 12,000 rpm for 12 minutes in an
Eppendorf Centrifuge 5402 (refrigerated microcentrifuge). The supernatant was
discarded and the pellet dissolved in the same amount of 70-80% EtOH as was used fOf
the 100% EtOH. After a 5-minute incubation at -20°C, the sample was spun again at 4°C
and 12,000 rpm for 12 minutes and the supernatant discarded. The pellet was then dried
in a Labconco Centrivap Concentrator and stored at -20°C until needed. For time trials,
the 10% Chelex protocol was started at the end of the exposure time and the supernatant
stored at -20°C until the rest of the incubations were complete fOf collected ethanol
precipitation.

Phenollchloroformlisoamyl alcohol (PIC/I) equilibraMn and DNA e.'Ctraction
Before the DNA (both mitochondrial and genomic) was extracted, the
phenoUchloroform/isoamyl alcohol mixture (25:24: 1 ratio) had to be equilibrated. 20 mL
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of clear P/CII (Fisher) was combined with 20 mL of O. 5 M Tris (pH 8.0) and stirred
vigorously in a hood for 15 minutes. The aqueous Tris layer was aspirated off the top
and replaced with 20 mL of 0.1 M Iris (pH 8.0). The 15 minute stir was repeated and the
aqueous layer aspirated off again. This stirring and aspiration was repeated once more
with another 20 mL aliquot of 0.1 M Tris (pH 8.0). The equilibrated P/CII was then
stored in a dark reagent bottle at 4°C under a layer of 0.1 M Iris (pH 8.0) until needed.
DNA was extracted from liver homogenate by first adding an equal volume of
equilibrated P/CIl to the homogenate sample, vortexing briefly, and spinning in a
microcentrifuge for 60 seconds. The top/aqueous layer was then moved to a new
microcentrifuge tube while the P/CIl and fluffy protein layers were discarded. An equal
volume o.tchJoroforrn was added to the aqueous layer, vortexed briefly, and spun for 30
seconds in a microcentrifuge. The lop/aqueous layer was then moved once again to a
new microcentrifuge tube while the chloroform layer was discarded. This aqueous layer
was then ethanol precipitated and dried as described above in the 10% Chelex extraction
protocol, dissolved in 1 mL of dH 20, and the A260 taken relative to a dH 20 blank. This
process was done so that the amount of DNA obtainable from 100 !JL of homogenate
could be determined (since 1 ODu>o is equivalent to 50 Ilg of DNA)

A. Standard Polymerase Chain Reaction

PCR Prep and ThemtaJ Cycling Programs
Into pre-labeled peR tubes, 0.75 11M of each primer (from lOT DNA), 1 mM
dNTPs (deoxynucleotides), 2.5-3.7 roM MgCh, and 1.5 U of AmpliTaq Gold polymerase

5\

(both from a GeneAmp Gold PCR Reagent Kit from ABI Biosystems) were combined in
Ix PCR Gold buffer along with the proper amount of template DNA obtained ITom PfCII
extraction and EtOH precipitation (Tables I & 2). The final volume within the PCR
tubes was 50

~

so the DNA pellet was dissolved in the proper amount of dH 20 to

achieve both this total volume and the optimal amount of template DNA needed for PCR.
There were three pairs of primers used in this experiment to amplify a 400 bp region in

cytochrome b of the mitochondrial genome, the open region of the
the condensed chromatin region just upstream of the

~-globin

~-globin

domain, and

locus. The cytochrome b

primers were ITom Kocher et ai. and amplify the same region of cytochrome b in many
different species while the open and closed chromatin primers were designed using the
OLIGO ~gram and a copy of the ~-globin sequence from Felsenfeld at NlH.
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If

several of the same type of peR reactions were being prepared simultaneously, a master
mix containing the lOx buffer, dNTPs, MgCh, Taq and primers was made first, vortexed,
spun down, and then divided up among all of the PCR tubes. The PCR reagent amounts
used were almost identical for all primer sets used in this study. The Mg1 + concentration,
however, varied for each primer set because of differences in primer composition and
thennal cycling conditions.

Primer Target
Cytochrome b "lI

Primer Name
L14841
H15149

Open chromatin
(~-globin)

Closed chromatin

Open-F
Open-R
Closed - F2
Closed- R

Sequence
5'-AAA AAG CIT CCA TCC AAC ATC
TCA GCA TGA TGA AA
5'-AAA CTG CAG CCC CTC AGA ATG
ATA ITT GTC CTC A
5'-GeC TGG CCT CTC ITT ACC TGT
5' -GCA ATC CTC TCT ACC TGG GeT
5'-AGT ACT GCC GTG TGT ITG CTC
5'-TAC AGe CCT CTC AGe AAG TAA

(~-globin)
Table I. Pnmers used to amphfy 400 bp regIOns ill mitochondrial DNA and open and closed chrornalln reglOllS m
genomIC DNA. The rntDNA primers are from Kocher et al. while tbe open and closed chromatin primers were
147
designed using OLlGO.
All primers obtained from fDT DNA.
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Reagent

cytochrome b

open chromatin

lOx peR Gold buffer
10 mM dNTPs
25 mMMgCh
Taq polymerase [5U/j.!l]
Primer # 1 (50 J-LM)

5 ~L
5 !-tL (1 mM)
7.4 flL (3.7 mM)
0.25 !-tL
0.75 !-tL (0.75
J.lM)
0.75 !J.L (0.75
liM)
10 ng

5,...L
5 !-tL (1 mM)
7 )..LL (3.5 roM)
0.25 )..Ll
0.75 !-tL (0.75 )..LM)

Primer #2 (50 !J.M)
Total DNA added

0.75 !-tL (0.75 liM)
25 n.g

closed
cbromatin
5 IJ.L
5 !J.L (l mM)
5 )..LL (2.5 mM)
0.25 III
0.75 )..Ll (0.75
!-tM)
0.75 !-tL (0.75
J-LM)
100 ng

Table 2. PeR s~tup for all three DNA targets ID thIS study. The concenO'anon amounlS III parentheses are the final
concenmuions of the reagent within the 50 I!L peR reactions. The cytochrome b PeR recipe is an adaptation of the
ooe given by Kocher el al. 1'1

Thermal cycling was performed on a GeneAmp peR System 9700 from Applied
Biosystems. The cycling program for each primer set differed in annealing temperature,
number of'cycles, and the length of each cycle phase. The thermal cycling program for
the cytochrome b primers had longer phase cycles than the programs used for the open

and closed chromatin pairs but since this cycling program worked well for the
cytochrome b primers, it was not adjusted (Figures 18 & 19).
35 cycles

93°C

930C

2:00

1:00

00

Figure 18. Thermal cycling program for cyrochrome b primers. W
30cydes

5'00

0:30

00

MOC

940C

5-00

0:30

00

Figure 19. Thermal cycling programs for open (lap) and closed (bonom) chromatin primers.
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1.5% agarose gel
PCR products were run out on a small or large 1.5% agarose gel to visualize the
products and verify amplification. Six tenths of a gram of agarose were added to 40 mL
Ix TBE (89 mM Tris, 89 mM boric acid, 2 roM Na2EDTA) for the small gel and 1.8
grams of agarose and 120 mL of Ix TBE for the large gel. The solution was then
microwaved in short bursts to dissolve the agarose without causing the mixture to boil
over. The heated agarose was allowed to cool to circa 50°C and then poured into a gel
cast. A comb was inserted and the gel allowed to polymerize at room temperature.
15 ~tL of each PCR sample was mixed with 3 ~l of 6x agarose dye (0.025 g
bromophenol blue and 4.0 g sucrose brought to a total solution volume of 10 ml with
dH 20). Each agarose gel also contained a marker lane composed of 10 III of low Mass

DNA ladder (lnvitrogen) and 2 ilL of 6x agarose dye. The polymerized gel was put into
the running apparaus, immersed in Ix TBE, and the sample mixtures loaded into separate
lanes. The gels were run at 70 V (small) or 90 V (large) until the dye front traveled 3/4
of the way down the gel.
To visualize the bands, the gel was removed from the running apparatus and
placed in 100 mL of 5 J.!M ethidium bromide if a small agarose gel or 500 mL of 10

~M

ethidium bromide if a larger one. The gel was then shaken at 60 rpm for 10 (small) or 20
(large) minutes and viewed under an ultraviolet light.

Band sequencing
Once PCR was completed on one of the three regions and run out on a large 1.5%
agarose gel (for better resolution), the sample was sequenced by cutting its band out and
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placing it in a 0.45 J.lrn cellulose acetate All-Tech spin column. The column was spun at
one or two minute intervals at l2,000 rpm and 4°C in an EppendorfCentrifuge 5402.
The liquid was gathered into a separate tube and the process repeated until all of the
liquid was retrieved. PfCII and chlorofonn extraction was then perfonned (as described
above). After the chloroform extraction, a 1120 volume of 10M Nl-LOAc and 2 volumes
of 100% EtOH was added to the aqueous layer. This solution was stored at -20°C
overnight, spun at 12,000 rpm and 4°C for 30 minutes in a EppendorfCentrifuge 5402
the next morning, and the supernatant discarded. After drying the pellet in a Labconco
Centrivap Concentrator, it was dissolved in 20 J.lL of dH20. 1 J.lL of this mixture was
combined with 5 I-lL of 6x agarose dye and run out on a small gel along with a lane of the
Low M~'DNA Ladder to quantitate by eye the amount of DNA present in 1 ilL of this
DNA solution. From this information, the amount of DNA solution needed for 20-40 ng
of DNA was calculated. Two cycle sequencing reactions were then run for each DNA
solution with each cycle sequencing reaction using only one primer. 20-40 ng of DNA
was combined with 4.0 JlL of BigDye Mix (from BigDye Tenninator v 3.0 Cycle
Sequencing Ready Reaction by ABI Prism), 0.64 picomoles of primer, and enough dH 20

°

to bring total reaction volume to 1 1-lL. The same thermal cycling program was run on
this BigDye reaction as before. For each cycle sequencing reaction, 0.8 mL of dH 20 was
added to a Centri-Sep spin column with septa (princeton Separations). The columns were
shaken and then allowed to settle by opening the columns, placing them in 2.0 mL
microcentrifuge tubes, and letting them sit and drain at room temperature. The columns
were then spun at 3000 rpm at 20°C for 2 minutes in an Eppendorf Centrifuge 5402 to
finish draining the columns. Placing the prepared columns into clean 1.5 mL
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microcentrifuge tubes, one tube of PCR product was added to each column and then spun
again at 3000 rpm and 20°C for 2 minutes in an Eppendorf Centri fuge 5402 to collect the
purified PCR product. The PCR samples were then dried in a Labconco Centrivap
Concentrator and were stored at -20°C until they were sequenced. Sequencing followed
the nonnal protocols for an ABI Prism 3 10 Genetic Analyzer.
Alternatively, several sequences were sent out to MWG-Biotech at 40-80

ng/~L

along with 20 J.LM of each primer. These samples, before agarose gel quantitation, were
purified either by agarose/column purification for the cyt b and closed chromatin samples
(peR product bands cut out of a 1.5% small agarose gel, spun through 0,45 !lID cellulose

acetate All-Tech spin column at 3500 rpm in an EppendorfCentrifuge 5402, ethanol
precipitatid and air-dried overnight) or using a E.Z.N.A.Cycle-Pure Kit (Omega Bio-tek)
for the open chromatin sample (following directions provided with the kit except used 5
volumes of Buffer CP for each peR sample and spun at 10,000 rpm in an Eppendorf
Centrifuge 5402 before a final ethanol precipitation and pellet air-dried overnight).

B. Quantitative peR

5 '-Radiolabeling ojprimers
One of the two primers necessary for amplification of the target region was
selected to be radiolabeled. 2!J.L of this primer's 50

~

stock was combined with 2 J.LL

of lOx T4 polynucleotide kinase (pNK) buffer from New England BioLabs, 1 or 2 J.LL of
y_32 p

ATP (Amersham) and 14 or 15 J.LL dH2 0 for a total volume of20!J.L in a 1.5

m.icrocentrifuge tube. After a short spin, I J.LL of PNK (l0 U/l-lL) from New England
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BioLabs was added to the tube. The microcentrifuge tube was incubated for 30 minutes
at 3rC and then ethanol precipitated using 2.1

!J.L of3

M NaOAc, 200 J-lL of 100%

EtOH, and 200 I-lL of 70% EtOH as described in the DNA extraction section above. The
hot primer was stored at -20°C as a dried peJlet until needed.

peR Prep and Thermal Cycling Programs
The PCR protocol was almost identical to the one for normal PCR described
above. Instead of the using both 50

~

primer stock, one of the primers was replaced

with the radiolabeled primer pellet. For each PCR reaction in a thermal cycling run, 1 I-ll
of dH 20 was added to the radio labeled primer pellet and an additional 1 f.lL of dH20
added if r~:rming a primer only lane in the upcoming polyacrylamide gel (below). Once
the primer pellet was dissolved. a master mix was made using both primers (one being
0.75 I-lL of hot primer for each reaction), lOx PCR Gold buffer, dNTPs, MgCh and
AmpliTaq Gold polymerase as described in the normal PCR procedure. Once the master
mix, proper amount of DNA, and dH 20 were combined to make a 50 (..lL peR sample,
the radioactivity of each PCR tube was measured using a Geiger counter to make sure
that all of the PCR samples in a reaction series had the same amount of radioactivity.
The thermal cycling programs used fOT the quanitative peR were the same as those used
in the normal PCR and the reaction tubes stored at -20°C afterwards.

8% polyacrylamide gel electrophoresis (PAGE) - Large gel
Forty-nine and a half grams of urea was dissolved in 10 ~ of lOx TBE, 20 mL of

40% acrylamide (19: I), and 15 mL of dH20 using low heat. The plates (35.5 em x 43 em
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and 35.5 em x 41.3 em) were then cleaned with soap and distilled H20 and one side of
each plate (the inside surface) was cleaned with Gelplate-c1ean solutions I and II from
Geno Technology, Inc. and EtOH. The inner surface of the larger late was then coated
with Sigmacote (Sigma Chemical Company), wiped dry, sprayed with dH 20, and dried
again. 0.5 roM spacers were inserted along the sides and the bottom was sealed with
tape. The gel apparatus was then clamped along the two sides and stood nearly upright.
The gel solution was filtered using vacuum filtration and 350 III of 20% APS
(ammonium persulfate) solution was added.. Six mL of this gel solution was then
removed, 6

~

ofN,N,N',N'-tetramethylenthylenediamine (TEMED) added to it, and 1

glass pipette of this mixture (-1.5 mL) was added to each side of the gel apparatus to
creat~

a p.hlg. This was allowed to polymerize at room temperature using the 3 mL left

over as an indicator. Thirty-five lAL of TEMED was added to the remaining gel solution,
stirred, the gel apparatus placed nearly horizontal at a slight slant, and the gel was poured
trying to avoid any air bubbles. A 0.5 mM comb was inserted in the top, covered in
Saran Wrap, and then clamped in place. The gel was allowed to polymerize at room
temperature. Once polymerized, the comb, clamps, and tape at the bottom were removed.
The gel was placed in a running apparatus with Ix TBE (89 roM Tns, 89 rru\tf boric acid,
and 2 mM Na2EDTA), the wells outlined with a marker, and pre-run for 1 hour at 65 W.
PCR samples (50 !J.L) were ethanol precipitated, combined with 10 JlL of 5M urea dye
containing 0.1 % xylene-cyanol, and loaded into the gel after their radioactivity had been
measured.. The gel was run out 20 em down the gel at 60 W.
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8% native PA GE

Glass plates (one each of 19.7 em by 19 em and 19.7 cm by 15.9 cm) were
cleaned vigorously with soap and water. Then one side of each plate (which will become
the inner surface) was cleaned with Gelplate-c1ean solutions I and II from Gena
Technology, Inc. and EtOH. 1.5 mM spacers were inserted between these two plates on
the bottom and two sides and then the two plates clamped together along these sides.
In a beaker, 28 mL of dH20, 8 mL of 40% 19: I acrylamide (acrylamide:bis
acrylamide) from Fisher, and 4 mL of lOx TBE (890 mM Tris, 890 roM' boric aci~ and
20 roM Na2EDTA) were combined with 350

~

of20 % ammonium persulfate (APS).

20 III ofTEMED was then added, the mixture stirred with a pipette, and then quickly
poured iQ,J:letween the gel plates at a slight angle while removing any air bubbles. A 1.5
mm comb was inserted into the top, clamped into place, and covered with plastic wrap.
The gel then sat flat for at least 1 hour to polymerize. The clamps, bottom spacer, and
comb were removed after this hour wait and the gel (still between the two glass plates)
clamped onto a running apparatus. After the running apparatus was filled with Ix TBE,
the wells were blown out with a needle and any air bubbles present below the gel
removed. The gel was then pre-run for at least 1 hour at 250 V before the samples were
run. 25 ilL of peR sample and I ilL of the radiolabeled primer solution made earlier or
25 IJ.l of a negative control were each combined with 5 ilL of 6x native dye (10 mL of
glycerol, 10 mL of dlhO, and 0.02 grams xylene-cyanole) before loading into the 8%
native gel. Once the pre-run was finished, the wells were once again blown out and the
samples were loaded after their radioactivity was once again measured (to keep the
process quantitative). The samples were run out 5 em down the gel at 250 V.
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Phosphorimaging and band quantitation
Once the gel was run, the plates and spacers were removed so that one side of the
gel was placed on filter paper and the other side covered with plastic wrap. The gel was
placed with the filter paper side down onto a Drygel Sr. Slab Gel Dryer SE 1160 (Hoefer
Scientific Instruments) and dried 60 minutes with heat and 30 minutes without heat. The
excess filter paper was trimmed off> the plastic wrap removed., and the gel placed on a
GS-505 Sample Exposure Platform from BioRad. The gel was covered with a 23 x 28
cm Screen Guard Protective Film from BioRad and exposed to a reset Bio-Rad Molecular
Imaging Screen - BI for at least four hours (screens were reset each time by a 10 minute
exposure to a GS-505 Screen Eraser made by BioRad). A GS-505 Molecular Analyst
then sca~ed the exposed phosphorimager and the image analyzed using Molecular
Analyst software from BioRad (version 2.1.2). If quantitating the results, equal-sized
boxes were drawn around each band and then integra.ted by the software to calculate the
intensity of each band. The band density detennined by the Molecular Analyst software
for each band was compared to the control band density using the Poisson equation.
Lesion frequency under this equation is equal to -In (~/~) where

A<J is the sample band

density and ~ is the control band density.l4S The lighter the peR band relative to the
control, the higher the DEB lesion frequency.
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RESULTS

This project first focused on the optimization of conditions for peR on the
cytochrome b region in the mitochondrial genome and open and closed chromatin regions

within the {3-g1obin region in the nuclear genome. The {3-g1obin primer pairs used here
replaced Taqman primers used previously by Andre Pilon '03 because those primers
amplified 100 bp regions, which were too short and thus indistinguishable from the PCR
remnants on a 1.5% agarose ge1.

9

Using the f3-globin sequence provided by NIH,

together with the OLIGO program, we designed replacement primer pairs that amplify
-400 bp regions in the open and closed chromatin regions.

ME!-l, concentration

Optimization of

First, the amount of Mg 2+ was optimized for these three different targets. Using
the literature Mg 2 concentration for the cytochrome b primers as a basis, PCR runs were
-l,

conducted at varying Mg 2+ concentrations and run out on small 1.5% agarose gels. 14S An
excess of DNA ()..Lg scale) was used along with the other reagent amounts suggested in
the GeneAmp Gold PCR Reagent Kit from ABI Biosystems (Table 2 except 1 J.lM of
each primer). The concentration that gave the brightest PCR product with the least
amount of unused primers was selected: 3.7 mM Mg 2+ for the cytochrome b primers, 3.5
mM Mg 2 + for the open {3-g1obin primers, and 2.5 mM

Mi+ for the closed {3-globin

primers (Figure 20).
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Stop Assays
With PCR conditions optimized, the next step was to test PCR as a stop assay
using the cytochrome b primers since DNA molecules with a DEB lesion preswnably
break at the alkylation site during thermal cycling because of their heat lability. Thus,
there should be a series of bands on a polyacrylamide gel each of which corresponds to a
different DEB lesion location. A large polyacrylamide gel was run on primer-only
samples, control samples with one or both primers (second primer was not radiolabeled),
and DEB exposed (250 mM) samples with one or both primers (second primer was not
radio labeled) using the 10% Chelex protocol to isolate the mitochondrial DNA. The
control samples had a PCR product band (with the exception of C3 which appeared to
have.twQ,J)roduct bands) while the DEB-exposed samples did not have any PCR product
bands at all (Figure 22). A similar experiment was run on control or DEB-exposed
samples (this time exposed to either 25 or 2.5 mM DEB) with a similar primer
composition to see if lower concentrations of DES would produce a series of fragments
from PCR.. All samples (control and DEB-exposed) that included the second primer in
the pair had a single PCR product band while those lacking the second primer had no
PCR product bands at all (Figure 22). The presence of a PCR product band in the DEB
exposed samples containing both primers, however, seemed to indicate that QPCR
measurement of lesion frequencies might be possible.
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recorded below (Figure 23, Tables 3 and 4). Lesion frequency is -In(AoIAc) where AD
is the intensity of the PCR band from the DEB-exposed sample and Ac is the intensity of
the peR band from the control sample.

The irreproducible nature of these results

necessitated an alternative DNA extraction protocol - one believed to stop DEB/DNA
reactions after DNA extraction from the homogenate for use in the time trials.
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Figure 23. Gel from Trial 2 in Table 3. Samples on the left are the varying concentration samples from
250 mM down to 0.25 mM, sample C is the control sample. and samples on the right are the varying time
samples from 60 to 0 minutes. Arrow indicates PCR product bands.

Trial!

Trial 2

TriaJ 3

Trial 4

250mM

N/A

1.901

0.478

2.861

25mM
2.5 mM
0.25 nuVl
Omin
15 min
30min
45 min
60min

N/A
N/A
N/A
0.414
0.726
1.588
N/A
2.057

0.804
1.627
1.203
0.470
0.956
1.754
N/A
2.628

0.138

1.857
1.160
0.510
1. 714
2.429
2.281
2.332
2.154

Experiment
Type

Varying DEB
Concentration

Varying Time

-1.37

0.470
0.659
0.390
N/A*
0.348
0.475

Table 3. LesIon frequencies of four QPCR trials USing varymg amouncs of DEB or varymg exposure Urnes. For
varying DEB conceno-ahon., incubation was for 1 hour. If varying exposure lime, 250 roM DEB was used. *Discarded
dal.ll point due to low councs or low PeR volume.
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[DEB] Used

Exposure

Trial #1

Trial #2

Trial #3

Time

25mM

2.5mM

0.25 mM

omin
15 min
30min
45 min
60 min
o min
15 min
30 min
60 min
omin
15 min
30min
60 min

0.262
0.379
0.141
-0.073
0.003
-0.117
-0.190
-0.089
-0.012
-0.006
-0.001
-0.031
-0.028

0.321
0.042
-0.093
-0.118
-0.013
0.089
0.307
0.399

Table 4. Lesion frequencIes ofthrec QPCR tnaIs usmg varymg exposure TImes 10 25, 2.5, or 0.25 mM DEB.

Quantitative PCR: Phase 2 - Switch to phenol/chloroform/isoamyl alcohol extraction
In'iight of these results, similar QPCR experiments were conducted with the
phenol-chlorofonn extraction protocol described in the Material and Methods section (to
stop DEB reactions during time trials). Again, excess DNA was used for each
experiment and a primer only lane was also run. In each QPCR run, there was one
sample containing 250 mM, 25 mM, 2.5 roM, and 0.25 mM DEB (Figure 24, Table 5).

Quantitative PCR: Phase 3 - Clustering ofsamples by DEB concentraton
Next, samples were clumped together in the same QPCR run by DEB
concentration - one set of250 mM or 25 roM samples. Excess DNA was still used in
each sample and extracted using the equilibrated phenol-chloroform method (Figure 25,
Table 6).
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0.25 2.5
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Figure 14. Gel from QPCR .ttl in Table 5. P is the radiolabeled primer only lane. C is the control sample, and the
numberoo lanes are the respective concentrntions of DEB for the exposed samples. Arrow indicates peR product
bands.

QPCR#
1
}.;i.

5
6

250 roM DEB
2.962
0.054
-0.510
-2.500

25 mMDEB
2.682
-0.079
1.208
-3.2655

2.5 mM DEB
1.3898
0.117

1. WI
-0.3281

0.25 mMDEB
3.1613
0.091
-2.368
-0.9758

Table 5. lesIon frequencIes ofPCR samples usmg DNA exposed to 250, 25, 2.5, and 0.25 mM DEB for 30 mmutes.

c

2S0mMDEB

Figure 25. QPCR A from Table 6 run out on an 8% native polyacrylamide gel. The P lane is the primer
only sample. C is the control sample, and the 250 mM DEB lanes arc the DEB-ex.posed samples (30
minutes). Arrow indicates PCR product bands.
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OPCR#
A

250 mM DEB
-0.7381, L7252, 0.4613, -0.6312

25 mM DEB
-0.500, -1.153, 1.339

B
C

0.6224,0.8128, 1.147,0.9923,
0.2658
0.6060, 1.016,0.6630,0.7534

D
E

N/A (No control)

F
G

0.4808,0.5105,0.6132,0.9878

0.4780, 0.7674, -0.9703, -0.7206
-1.2497, -0.7857, -0.0525, -1.3451

H

Tll.ble 6. Lesion frequencIes of vanous peR samples using DNA exposed to 250 or 25 mM DEB for 30 minuteS.
Lesion frequency calculaled using the Poisson equation and the intensity of lhe control band in the 8% denaruling
polyacrylamide gel. Samples G and H contained two control bands whose intensities were averaged to calculate the
lesion frequenCies.

Quantitative peR: Phase 4 - Determining Limiting reagent amount a/tempLate DNA
After the experiments done in phases 1-3, reference to the background literature
on QPCrt~evealed that the template DNA must be the limiting reagent in the polymerase
chain reaction. 148 Further QPCR trials were conducted with the cytochrome b primer pair
to obtain a template DNA amount such that there is a linear decrease in PCR product as
the amount oftempJate DNA is reduced (as measured by 8% denaturing PAGE and
phosphorimagery). This QPCR optimization was conducted on the cytochrome b, open
chromatin, and closed chromatin primer pairs and the initial DNA amounts being used in
phases 1-3 were found to be in excess for all three targets (data not shown). Further
experimentation found that the limiting amount of total ONA for the cytochrome b, open
chromatin, and closed chromatin primers were 10 ng (Figure 26),25 ng, and 100 ng
respectiveIy.
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~

Open
C

D

Closed
C

D

C

D

Figure 27. QPCR trial #1 run out on an 8% native polyacrylamide gel. Control (C) and DEB-exposed (D) QPCR
samples are paired together for the open, closed, and cytochrome b primer pairs (left to right). Arrow indicates PCR
prodUCI bands.

peR product sequencing
The final part of this research project was the sequencing of the three peR si tes.
In the first attempt using an older protocol, the final reaction mixtures for the sequencer
either contained too much DNA or were too contaminated. As a resul~ the second
attempt used quantitation of the amount ofPCR DNA (20-40 ng) being used in the cycle
sequencing reactions (Figure 28). This attempt also failed to give DNA sequences for
these regions due to technical problems with the sequencer and the new BigDye Mix
v3.0.
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DISCUSSION

The polymerase chain reaction has become a powerful molecular biology
technique in both forensics and medicine. Now this procedure is being adapted to
measure certain types of DNA damage by quantitating the results of the polymerase chain
reactions. QPCR is still a relatively new technique and its methodology and even its
validity as a testing method are still being determined. Using DEB and chicken DNA,
this experiment not only attempted to measure the effectiveness of DEB as a DNA
binding agent but also looked into the effectiveness of QPCR as a new analysis method.
Before actual experimentation commenced, reaction conditions bad to be
optirnize<t-to maximize the amount of PCR product produced, a potentially long and
tedious process. First., the concentration of Mg2+ needed to be optimized for the primer
pair being used since Mg

2

+

is a critical cofactor in DNA polymerases. Using the

literature concentration ofMg

2

+

used for the cytochrome b primer pair as a reference,

repeat optimization of the cytochrome b primer pair went relatively quickly.147 Then
starting with the concentration of Mg 2+ for the cytochrome b primer pair, the same
optimization procedure was performed for the open and closed f3-globin primer pairs.
Similarly, the concentration of primers was also optimized. Starting with 1 f.J.M of each
(1 ilL of 50 IlM stock), the primer concentration for the cytochrome b and both the open
and closed f3-g1obin primer pairs was reduced to 0.75

~M.

Our first attempts at using peR as a stop assay was not successful. Since a DNA
sample containing a N7-N7 cross-link falls apart when heated, it was also believed that
the DNA double strand would break at the lesion producing a series of fragments. These
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fragments could be amplified (using one of the two primers) to give a band on a
polyacrylamide gel. This would then allow the locations of DEB cross-Iioking to be
mapped using length of the DNA fragment and which primer produced it. In the first
attempt (250 mM DEB for DEB-exposed samples), there were no PCR bands for any of
the DEB exposed samples and PCR band(s) for all control samples (Figure 22). The lack
of a series of bands in the DEB-exposed samples seem to indicate that the DEB-exposed
DNA molecules fragment upon heating in such a way that PCR amplification is not
possible on the remnants. A similar attempt with lower concentrations of DEB (25 mM
and 2.5 mM) had a single PCR band for any sample (control or DEB-exposed) that
contained both primers but no bands at aJl if one primer was lacking (Figure 22). Again,
a series qf DNA fragment bands was not seen in the DEB-exposed samples and thus the
attempts at using PCR as a stop assay were halted. The presence of PCR bands in the
DEB-exposed samples containing both primers, however, suggested the use of QPCR for
measuring DEB lesion frequencies in our three targets and this avenue of research was
pursued for the rest of this project.
2

It is vital at this point to note that the Mg + and primers were the only two
reagents optimized initially before QPCR experiments began. As can be seen in the first
sets of peR data, there was also no recognizable correlation between DEB exposure and
lesion frequency despite the fact that DEB should inhibit PCR amplification (Tables 3-6).
Slight adjustments were made to make the QPCR more unifonn between individual trials
- running samples with one DEB concentration together and using a master mjx to make
the radioactive count unifonn between samples (and thus maintain quantitativity).
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Samples that did not have the same volume or radioactivity were discarded since accurate
comparisons with the controls and thus accurate lesion frequencies would not be possible.
For the time trials in Table 3 and 4, increased exposure time to a fixed
concentration of DEB with the old 10% Chelex protocol also did not cause any consistent
increase in lesion frequency. This seemed to indicate that the 10% Chelex protocol might
not stop the DEB's cross-linking reaction with DNA. Consequently, the DNA extraction
protocol was switched to a pbenol-chlorofonn extraction that was expected to better stop
the cross-linking reaction. Time trials using this protocol, however, have not yet been
attempted and should be done in the near future to validate the use of phenol-chlorofonn
extraction in such trials.
: f\J:hange in extraction protocol and use of a master mix did not improve the
consistency of the results (Tables 5 and 6). There was still not a clear relationship
between DEB concentration and lesion frequency. Clustering of PCR runs with the same
DEB concentration also did not lead to a clear DEB concentration/lesion frequency
correlation (Table 6). During our search for why consistency was so poor, it was realized
(upon consultation with background literature on QPCR) that the DNA must be the
limiting reagent in order for QPCR to be used as a measure of DEB damage. 14S
OthelWise there might still be enough non-damaged DNA after exposure that PCR can
proceed at the same level as in a control sample with excess DNA, which would defeat
the purpose of using QPCR to quantitate the DEB damage. Up until this point the
amount of template DNA being used in each PCR was not even consistent (which may be
the cause of our lack of consistency in our results) much less limiting. As a result, the
amount of DNA was first optimized for normal PCR to give a starting amount of 2.5 Ilg.
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From there, QPCR trials were conducted with lowering amounts of DNA until there was
a linear decrease in peR product with DNA amount. This gave a final DNA amount of
lOng for the cytochrome b primer pair: 25 ng for the open chromatin primer pair, and
100 ng for the closed chromatin primer pair. Since there are many more copies of
mitochondrial DNA than genomic DNA in a given cell, the optimized amount of DNA
should be much higher for the

~giobin

primer pairs that the cytochrome b primer pair.

With this final optimization of the QPCR process, testing of lOng of DNA
exposed to 250 mM, 25 mM, or 2.5 mM DEB revealed in very preliminary studies that
only 250 mM DEB caused measurable inhibition ofPCR. After exposing chicken DNA
to 250 mM of DEB for 30 minutes, the next QPCR trials involved comparing the lesion
frequenc~ for

these three different sites (Table 7, Figure 29). Once again, the

consistency of the data cannot be confirmed from these two replicate trials although
initial results do look promising between these two replicates.
Sequencing of the closed chromatin target was only completed after samples were
sent out for analysis and yielded over 300 bp of overlap between the two sequencing
trials (Table 8). When this sequence was compared to the ~-globin sequence provided by
NlH, there is no correspondence. If this sequencing data is accurate, then our closed
chromatin primer pair appears to be amplifying a completely different region of the
chicken genome. If this is the case, our experiments are undennined since there is no
way of ascertaining in which type of chromatin region this amplified sequence lies. It
would then be necessary to design another closed chromatin primer pair, optimize it for
QPC~

sequence its DNA target, and compare it to the

~-globjn

target Comparing this

300 bp sequence to the entire chicken genome (available at
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http://genome.wustl.edu/projects/chickeo),nomatcheswerefound.This seems to
suggest that the peR products that we sent for sequencing were actually from some sort
of contamination (like bacteria or yeast). Thus repeat sequencing must be done on all
three samples so that any adjustments (like designing new primer pairs) can be made and
these experiments may continue.
Assuming that proper primer pairs can be designed and tested, the next priority
should be achieving consistent lesion frequencies for all three targets exposed to 250 roM
DEB. Once accomplished, this information could then act as a stepping stone for the
next phase of research, measuring the repair rates of DEB damage within live chicken
cells. After exposure to 250 roM DEB for 30 minutes (cells centrifuged down and buffer
containirutthem replaced), live chicken cells could then be allowed to recover for varying
amounts of time. After the resting time elapses, the DNA can be extracted from these
lives cells and used for QPCR with the three different primer pairs. With a baseline
already established for each target in dead chicken cells (no repair mechanisms), the
repair rates at each target can actually be quantiated using QPCR. This could give
significant insight into both the action of DEB in vivo and the cellular response to this
toxin within different regions of the chicken'5 genome.

Overall, QPCR has the potential to be a powerful tool in measuring the DNA
damage caused by some DNA cross-linkers because of the inhibitory effect the cross
linker has on amplification. This technique, though, requires significant preparation
before actual testing begins. The concentrations of Mi-~ and primer must be optimized
for every new primer pair used in the process, the amount of DNA must be scaled down
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to the point that it is the limiting reagent in the QPCR process, and the PCR products
sequenced to confinn that desired target is being amplified.
Moreover. this QPCR technique is measuring the absence ofPCR product
assuming that the lack of product is caused by the cross-linking action of DEB. In reality
though, many other factors can cause inhibition of PCR amplification. Even with the use
of a master mix for PCR (which would presumably distribute any contaminants evenly
among all samples including the control and thus should not impact the calculated lesion
frequency for a given sample), consistency has been extremely difficult to obtain. This
might explain why the study that this QPCR work is based on only documented three
trials in their results. 147
: wtIile the experimental steps can be very time-consuming and further drawbacks
include lability of reagents and sensitivity to unknown factors, QPCR's ability to detect
and measure low levels of lesion occurrence cannot be understated. This same technique
for measuring the amount of DEB damage might also still be adaptable into a stop assay.
Ifthe DNA samples with a DEB lesion break at the lesion, partial amplification of the
remaining fragments could be run out on a polyacrylamide gel and thus map the locations
of DEB lesions in a known sequence of DNA. Initial indications, however, seems to
indicate that this type of fragmentation does not occur although more experiments need to
be carried out to corrfum these indications.
Thus, QPCR has great potential to be a standard tool in the investigation of DNA
cross-linkers although its development is still in the preliminary stages. Extreme care is
needed for this technique and a lot of preparation must be carried out before any real
experimentation can begin. While the reliability and consistency ofQPCR are unclear in
78

this series of experiments, the potential does exist and can be harnessed by a well-trained
and experienced technician.
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